Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 4.9% - Should You Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) shares were down 4.9% during trading on Tuesday . The stock traded as low as $30.80 and last traded at $30.73. Approximately 103,624 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 682,991 shares. The stock had previously closed at $32.31.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AGIO. Scotiabank boosted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, December 9th. Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. HC Wainwright started coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. Finally, StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $56.57.

Remove Ads

Agios Pharmaceuticals Trading Down 1.8 %

The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of 2.67 and a beta of 0.90. The company has a fifty day moving average price of $33.17 and a 200-day moving average price of $40.85.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares of the company's stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.93% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC acquired a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $33,000. GF Fund Management CO. LTD. bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth $39,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at $53,000. Sterling Capital Management LLC raised its holdings in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares during the period. Finally, Quest Partners LLC lifted its position in Agios Pharmaceuticals by 139.6% during the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,283 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.